Your browser is no longer supported. Please, upgrade your browser.
INSY INSYS Therapeutics, Inc. daily Stock Chart
INSYS Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.21 Insider Own0.20% Shs Outstand75.39M Perf Week-14.32%
Market Cap559.39M Forward P/E- EPS next Y-0.19 Insider Trans42.41% Shs Float24.37M Perf Month-19.52%
Income-15.40M PEG- EPS next Q-0.15 Inst Own28.80% Short Float45.02% Perf Quarter-40.54%
Sales191.20M P/S2.93 EPS this Y-86.60% Inst Trans0.35% Short Ratio18.14 Perf Half Y-28.86%
Book/sh3.69 P/B2.01 EPS next Y42.40% ROA-2.10% Target Price14.40 Perf Year-32.85%
Cash/sh1.88 P/C3.95 EPS next 5Y28.00% ROE-2.60% 52W Range7.44 - 15.06 Perf YTD-19.35%
Dividend- P/FCF68.22 EPS past 5Y16.50% ROI2.40% 52W High-50.73% Beta0.85
Dividend %- Quick Ratio2.80 Sales past 5Y- Gross Margin87.90% 52W Low-0.27% ATR0.46
Employees423 Current Ratio3.10 Sales Q/Q-38.40% Oper. Margin-8.00% RSI (14)30.79 Volatility7.64% 5.33%
OptionableYes Debt/Eq0.00 EPS Q/Q-239.30% Profit Margin-3.70% Rel Volume0.94 Prev Close7.55
ShortableYes LT Debt/Eq0.00 EarningsNov 02 BMO Payout- Avg Volume604.82K Price7.42
Recom2.00 SMA20-15.66% SMA50-18.68% SMA200-31.34% Volume569,497 Change-1.72%
Oct-11-17Reiterated RBC Capital Mkts Outperform $14
Aug-04-17Reiterated RBC Capital Mkts Outperform $16 → $14
May-10-17Downgrade Piper Jaffray Overweight → Neutral
Dec-21-16Reiterated RBC Capital Mkts Outperform $23 → $16
Sep-22-16Reiterated RBC Capital Mkts Outperform $32 → $26
Apr-12-16Reiterated Jefferies Buy $23 → $17
Apr-11-16Reiterated Piper Jaffray Overweight $46 → $28
Feb-24-16Reiterated Jefferies Buy $36 → $23
Feb-01-16Reiterated RBC Capital Mkts Outperform $49 → $44
Mar-09-15Reiterated RBC Capital Mkts Outperform $65 → $71
Mar-04-15Reiterated RBC Capital Mkts Outperform $57 → $65
Dec-15-14Reiterated RBC Capital Mkts Outperform $53 → $57
Nov-12-14Reiterated RBC Capital Mkts Outperform $51 → $53
Nov-12-14Downgrade Oppenheimer Outperform → Perform $40
Oct-02-14Initiated RBC Capital Mkts Outperform $51
Aug-14-13Reiterated Oppenheimer Outperform $23 → $27
Jul-31-13Initiated Oppenheimer Outperform $23
Oct-11-17 08:39AM  After Gaining 16% Early Last Week, This Marijuana Stock Quickly Kissed It All Goodbye Motley Fool
08:00AM  Today's Research Reports on Trending Tickers: Insys Therapeutics and Zosano Pharma Corporation ACCESSWIRE
Oct-10-17 07:10AM  Featured Company News - INSYS Responds to the New Jersey Lawsuit Concerning Subsys, a Spray for Cancer Patients Containing Fentanyl ACCESSWIRE -9.35%
Oct-09-17 12:00PM  INSYS Therapeutics, Inc. to Participate in Oppenheimer Specialty Pharma Summit GlobeNewswire
09:00AM  INSYS Therapeutics Extends Compassionate Use Studies of Cannabidiol (CBD) for Refractory Pediatric Epilepsy GlobeNewswire
Oct-06-17 09:00AM  INSYS Therapeutics Addresses New Jersey Complaint GlobeNewswire
Oct-05-17 03:39PM  [$$] New Jersey Sues Insys Over Opioid Painkiller The Wall Street Journal
02:36PM  New Jersey sues painkiller company, calls its conduct 'evil' Associated Press
02:34PM  The Latest: Massachusetts settles with fentanyl company Associated Press
01:22PM  New Jersey sues Insys as opioid maker settles with Massachusetts Reuters
12:56PM  New Jersey is suing Insys over its opioid sales practices MarketWatch
12:29PM  New Jersey sues Insys as opioid maker settles with Massachusetts Reuters
09:50AM  Top 4 Marijuana Stocks to Watch Investopedia
Oct-03-17 07:01PM  Lifshitz & Miller LLP Announces Investigation of Alere Inc., Emergent BioSolutions, Inc., Frontier Communications Corporation, HSN, Inc., Insys Therapeutics Inc., LSB Industries, Inc. and Otonomy, Inc. PR Newswire
10:42AM  INSYS Therapeutics, Inc.: Gathering momentum, can it sustain its performance? Capital Cube
10:07AM  INSYS Therapeutics Completes Pharmacokinetics (PK) Study of Intranasal Naloxone for Opioid Overdose GlobeNewswire
08:20AM  Today's Research Reports on Stocks to Watch: Endocyte and INSYS Therapeutics ACCESSWIRE
08:15AM  INSYS Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : INSY-US : October 3, 2017 Capital Cube
05:16AM  Senvest Management shorting drug stocks Insys, Akorn, Fresenius Reuters
04:51AM  Sohn Conference: Raising the red flag on drug makers CNBC Videos
Oct-02-17 04:30PM  Why LiLAC Group, Insys Therapeutics, and Synchronoss Technologies Jumped Today Motley Fool +12.05%
Oct-01-17 11:31AM  This U.S. Marijuana Stock Is Arguably the Best on the Market -- and It's Dirt Cheap Motley Fool
09:12AM  INSYS Therapeutics Inc (INSY): How Does It Impact Your Portfolio? Simply Wall St.
Sep-29-17 09:00AM  INSYS Therapeutics Files New Drug Application (NDA) for Buprenorphine Sublingual Spray with FDA GlobeNewswire
Sep-28-17 05:10PM  Should You Invest in This Marijuana ETF? Motley Fool
Sep-25-17 10:40AM  ETFs with exposure to INSYS Therapeutics, Inc. : September 25, 2017 Capital Cube
04:47AM  This Marijuana Stock Is On an 8-Day Losing Streak -- Is It Time to Buy? Motley Fool
Sep-21-17 06:00PM  INSYS Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
04:01PM  INSYS Therapeutics Hires First Corporate Communications Leader and New Investor Relations Agency GlobeNewswire
Sep-20-17 07:30PM  Our 5 Top Picks For A Booming Marijuana Market
Sep-15-17 12:27PM  Montel Williams' Battle With Multiple Sclerosis And The Miracle Of Medical Marijuana Benzinga
08:33AM  Of the 14 Largest Marijuana Stocks, Only These 2 Are Down Over the Past Year Motley Fool
Sep-14-17 06:26PM  ETFs with exposure to INSYS Therapeutics, Inc. : September 14, 2017 Capital Cube
01:55PM  Company under fire for opioid marketing files patent suit Associated Press
Sep-13-17 11:41AM  INSYS Therapeutics, Inc. :INSY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 Capital Cube
07:23AM  3 PR Scandals Creating Intriguing Buying Opportunities Motley Fool
Sep-12-17 07:55AM  Have Investors Already Priced In INSYS Therapeutics Incs (INSY) Growth? Simply Wall St.
Sep-07-17 09:49AM  [$$] Opioid Maker Bent Rules to Get Drug to Patients, Senate Report Says The Wall Street Journal
Sep-06-17 07:16PM  U.S. senator reveals results of opioid inquiry into Insys Reuters
05:48PM  U.S. senator reveals results of opioid inquiry into Insys Reuters
02:51PM  [$$] Opioid Maker Bent Rules to Get Drug to Patients, Senate Report Says The Wall Street Journal
Sep-05-17 09:31AM  Why This Marijuana Stock Crashed 18.5% in August Motley Fool
Sep-01-17 12:08PM  5 of the Most Hated Biotech Stocks on the Market: Are They Buys? Motley Fool
09:45AM  Insys Addresses Arizona Attorney General Complaint GlobeNewswire
12:30AM  [$$] Arizona Accuses Insys of Fraudulently Marketing Fentanyl Painkiller The Wall Street Journal
Aug-31-17 03:53PM  Arizona accuses drugmaker Insys of fraudulent opioid marketing Reuters
01:25PM  AG's office files lawsuit against opioid manufacturer Insys Therapeutics American City Business Journals
10:39AM  [$$] Arizona Accuses Insys of Fraudulently Marketing Fentanyl Painkiller The Wall Street Journal
10:35AM  Arizona accuses Insys of fraudulent opioid marketing scheme Reuters
Aug-24-17 07:50AM  Corporate News Blog - Insys Therapeutics Releases Statement on Illinois Settlement; Provides Data against the Opioid-Induced Calamity in the US ACCESSWIRE
Aug-22-17 06:50AM  Insys Addresses Questions Raised by Illinois Settlement GlobeNewswire
Aug-19-17 12:03PM  3 Top Biotech Stocks Under $10 Motley Fool
Aug-18-17 03:27PM  Insys agrees to pay $4.45 mln to resolve Illinois opioid lawsuit Reuters
02:27PM  Insys agrees to pay $4.5 mln to resolve Illinois opioid lawsuit Reuters
Aug-14-17 08:34AM  This Struggling Marijuana Stock Finally Launched Its Highly Anticipated Drug Motley Fool
Aug-13-17 09:03AM  3 Marijuana Stocks That Could Make You the Most Money in the 2nd Half of 2017 Motley Fool
Aug-12-17 09:20AM  Edited Transcript of INSY earnings conference call or presentation 3-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-10-17 09:49AM  Nevro's (NVRO) Q2 Loss Wider than Expected, Revenues Beat Zacks
Aug-09-17 09:46AM  BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss Zacks
09:42AM  BioTelemetry (BEAT) Q2 Earnings Top, Revenues Meet Estimates Zacks
09:20AM  Myriad Genetics (MYGN) Beats on Q4 Earnings & Revenues Zacks
08:32AM  Penumbra (PEN) Loss Meets Estimates, Revenues Beat in Q2 Zacks
08:32AM  This Marijuana Stock Skyrocketed Last Week, While 3 Others Plunged Motley Fool
Aug-08-17 10:14AM  Henry Schein (HSIC) Q2 Earnings & Revenues Beat, View Intact Zacks -6.62%
08:50AM  Orthofix (OFIX) Earnings Meet, Sales Beat Estimates in Q2 Zacks
08:31AM  Haemonetics (HAE) Q1 Earnings Beat, Revenues Miss Estimates Zacks
08:17AM  Bio-Rad (BIO) Misses Q2 Earnings & Sales, Margin Declines Zacks
Aug-07-17 08:25AM  Insulet (PODD) Shows Strength: Stock Adds 7.1% in Session Zacks
07:43AM  Cardiovascular Systems Rides on Innovation Amid Several Woes Zacks
Aug-04-17 04:32PM  Pacific Biosciences (PACB) Posts Wider-than-Expected Q2 Loss Zacks
09:26AM  Wright Medical Group (WMGI) Q2 Loss Narrower than Expected Zacks
09:23AM  Inogen (INGN) Beats Earnings and Revenue Estimates in Q2 Zacks
08:50AM  Illumina (ILMN) Rides on New Products, Low Margin a Concern Zacks
08:49AM  Bruker (BRKR) Q2 Earnings & Revenues Beat Estimates, View Up Zacks
Aug-03-17 11:53PM  Insys Therapeutics reports 2Q loss Associated Press -8.91%
05:09PM  It's High Time For The Cannabis-Related Drug Pipeline Benzinga
12:10PM  Insys takes $4.5 million charge to settle Illinois opioid lawsuit Reuters
08:36AM  Agios Pharmaceuticals (AGIO) Looks Good: Stock Adds 5.1% in Session Zacks
08:09AM  Cardiovascular Systems (CSII) Posts Q4 Earnings, Revenues Top Zacks
06:50AM  Insys Therapeutics Reports Second Quarter 2017 Results GlobeNewswire
06:15AM  Investor Network: Insys Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-17 10:25AM  Illumina (ILMN) Tops Q2 Earnings & Revenues, Raises View Zacks
08:16AM  DaVita (DVA) Beats Earnings and Revenue Estimates in Q2 Zacks
Aug-01-17 10:35AM  VWR Corp (VWR) Beats Earnings & Revenue Estimates in Q2 Zacks
10:29AM  IDEXX Laboratories (IDXX) Q2 Earnings & Revenues Top, View Up Zacks
09:54AM  Hill-Rom Holdings (HRC) Beats Q3 Earnings, Misses Revenues Zacks
Jul-31-17 09:07AM  NuVasive (NUVA) Beats on Q2 Earnings, Retains 2017 View Zacks
09:03AM  Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2 Zacks
08:20AM  LeMaitre Vascular (LMAT) Worth a Look: Stock Jumps 19.5% Zacks
06:50AM  Insys Announces Availability of SYNDROS, the First and Only FDA-Approved Liquid Dronabinol, by Prescription GlobeNewswire
Jul-28-17 04:32PM  ETFs with exposure to INSYS Therapeutics, Inc. : July 28, 2017 Capital Cube
11:15AM  Abaxis (ABAX) Misses Earnings & Revenue Estimates in Q1 Zacks
11:04AM  GNC Holdings (GNC) Tops Q2 Earnings, Misses Sales Estimates Zacks
09:48AM  Align Technology (ALGN) Beats on Q2 Earnings and Revenues Zacks
09:46AM  QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View Zacks
Jul-27-17 12:14PM  McKesson (MCK) Misses Earnings Estimates in Q1, Raises View Zacks
09:17AM  Integra LifeSciences (IART) Q2 Earnings Meet, Revenues Miss Zacks
09:05AM  CONMED (CNMD) Earnings Meet, Revenues Beat Estimates in Q2 Zacks
Jul-26-17 11:04AM  LabCorp (LH) Beats on Q2 Earnings and Sales, Guidance Up Zacks
09:17AM  Chemed (CHE) Q2 Earnings & Revenues Rise Y/Y, View Revised Zacks
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JOHN N KAPOOR TRUST DATED SEPT10% OwnerAug 11Buy8.9317,500156,33842,447,810Aug 14 12:38 PM
Motahari SaeedPresident & CEOAug 10Buy8.925,50049,05615,400Aug 10 02:42 PM
FOURTEAU PATRICKDirectorAug 04Option Exercise1.6210,00016,20069,682Aug 04 05:33 PM
Motahari SaeedPresident & CEOJun 14Buy11.105,40059,9559,900Jun 14 03:19 PM
Vishnoi RohitDirectorJun 01Buy14.144,00056,5754,000Jun 02 03:14 PM
FOURTEAU PATRICKDirectorMay 26Option Exercise3.6310,00036,30059,682May 26 04:26 PM
MEYER STEVEN JDirectorMay 18Buy12.218,00097,68052,083May 18 04:48 PM
Motahari SaeedPresident & CEOMay 16Buy11.984,50053,9324,500May 16 08:53 PM
MEYER STEVEN JDirectorNov 04Buy10.7510,000107,48944,083Nov 07 10:14 AM